Drug Trial News

RSS

Eli Lilly announces inconclusive study results for mGlu2/3 in acute schizophrenia

Eli Lilly and Company has announced inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia.

29 Mar 2009

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

ARCA biopharma, Inc. has announced that data from the pivotal Phase 3 BEST trial of Gencaro (bucindolol hydrochloride) in patients with advanced chronic heart failure (CHF) was presented at the American College of Cardiology 58 th Annual Scientific Session being held March 29-31, 2009 in Orlando, Florida.

29 Mar 2009

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

Findings published in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo.

29 Mar 2009

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

Results from a new sub-analysis of the JUPITER study show that patients who attained a dual treatment target of LDL-C <70mg/dL and high-sensitivity C-reactive protein (hsCRP) <2mg/L with CRESTOR (rosuvastatin) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%, p=0.033) among men and women with low to normal cholesterol levels and elevated hsCRP.

29 Mar 2009

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p=0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

29 Mar 2009

A comparative analysis of four beta blocker trials

ARCA biopharma, Inc. has announced that a comparative analysis of primary endpoint data from four beta blocker trials was presented at the American College of Cardiology 58th Annual Scientific Session being held March 29-31, 2009.

29 Mar 2009

ArunA Biomedical to commercialize human embryonic stem cell derived mesenchymal cells

ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.

29 Mar 2009

Amicus Therapeutics presents positive results from phase 2 extension study of Amigal for Fabry disease

Amicus Therapeutics has announced positive results from its ongoing Phase 2 extension study of its investigational drug, Amigal (migalastat HCL) for Fabry disease.

29 Mar 2009

RegeneRx reports phase II venous stasis trial results

Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.

29 Mar 2009

Positive phase 3 uveitis trial results for voclosporin

Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.

29 Mar 2009

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems related to dementia.

29 Mar 2009

Oxycodone effective against shingles pain

The painkiller oxycodone is effective at treating the acute pain of shingles, an illness that often causes severe pain which can become long-lasting and sometimes even permanent.

26 Mar 2009

Rexahn Pharmaceuticals starts phase II pancreatic cancer trial

Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.

24 Mar 2009

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Radius Health ("Radius") announced today that the first patient has been dosed in the company's proof-of-concept Phase 2a study of RAD1901, an investigational selective estrogen receptor modulator (SERM) undergoing clinical evaluation for treatment of vasomotor symptoms (menopausal hot flashes).

24 Mar 2009

Orexo reports on efficacy study in allergic rhinitis with OX914

Orexo has reported clinical results from an experimental phase IIa safety and efficacy study in allergic rhinitis with OX914, the first compound in its Phosphodiesterase 4 (PDE4) inhibitor program.

24 Mar 2009

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase II clinical trial of cicletanine hydrochloride (cicletanine), an oral agent in development for the treatment of pulmonary arterial hypertension (PAH).

24 Mar 2009

Canadian researchers to launch clinical trial to determine efficacy of treating latent TB with four-month course of Rifampin

Researchers at McGill University in Montreal on Tuesday announced they will soon launch an international clinical trial to determine if latent tuberculosis can be treated successfully with a four-month treatment course of the TB drug rifampin rather than the standard nine-month treatment with the TB drug isoniazid, the CP/Toronto Sun reports.

24 Mar 2009

Phase II clinical trial of tuberculosis vaccine candidate to begin next month in South Africa

The Areas Global TB Vaccine Foundation next month will begin a Phase II clinical trial of a new tuberculosis vaccine candidate that aims to improve on the existing BCG vaccine, Bloomberg reports.

24 Mar 2009

Review of probiotics in the treatment of Irritable Bowel Syndrome

A review by researchers at Northwestern University (Chicago, IL.) and University of Michigan (Ann Arbor, MI) of the utility of probiotics in the treatment of Irritable Bowel Syndrome (IBS) found that Bifidobacterium infantis 35624 was the only probiotic strain out of 13 different individual strains or preparations reviewed to significantly improve symptoms of IBS, including abdominal pain, bloating and bowel movement difficulty.

23 Mar 2009

NEJM Letters respond to recent studies on malaria vaccines, treatments

The New England Journal of Medicine in its March 19 issue featured a letter to the editor written in response to a study published in its Dec. 11 issue reporting the results of the RTS,S/AS01E malaria vaccine trial.

23 Mar 2009

Drug Trial News

Eli Lilly announces inconclusive study results for mGlu2/3 in acute schizophrenia

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A comparative analysis of four beta blocker trials

ArunA Biomedical to commercialize human embryonic stem cell derived mesenchymal cells

Amicus Therapeutics presents positive results from phase 2 extension study of Amigal for Fabry disease

RegeneRx reports phase II venous stasis trial results

Positive phase 3 uveitis trial results for voclosporin

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

Oxycodone effective against shingles pain

Rexahn Pharmaceuticals starts phase II pancreatic cancer trial

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Orexo reports on efficacy study in allergic rhinitis with OX914

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Canadian researchers to launch clinical trial to determine efficacy of treating latent TB with four-month course of Rifampin

Phase II clinical trial of tuberculosis vaccine candidate to begin next month in South Africa

Review of probiotics in the treatment of Irritable Bowel Syndrome

NEJM Letters respond to recent studies on malaria vaccines, treatments

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News